Mal Madho, Kumar Ashok, Meraj Areeba, Devi Arooj, Mañego Alyanna Marie B, Anjum Zauraiz, Naz Sidra, Jamil Amna, Fatima Aliya, Kumar Besham
Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.
Internal Medicine, Dow University of Health Sciences, Karachi, PAK.
Cureus. 2021 Jun 30;13(6):e16067. doi: 10.7759/cureus.16067. eCollection 2021 Jun.
Omega-3 fatty acids have for long been shown to reduce the incidence of cardiovascular (CV) diseases. Omega-3 fatty acids mainly exist in the form of eicosapentaenoic acid (EPA) and docosahexaenoic acid in fish oils. Cod liver oil is found to have a high concentration of these omega-3 fatty acids. This study aims to explore the benefits of using cod liver oil in reducing the incidence of myocardial infarction (MI) among at-risk patients. Method: This open-label placebo-controlled two-arm interventional study was conducted in the internal medicine and cardiology unit of tertiary care hospital between January 2018 to January 2021. During this period, 870 patients at risk of CV events were enrolled in the study after obtaining informed consent. The study group received 415 mg cod liver oil daily, in addition to their current treatment, in a bottle without label and the control group received no additional treatment to their standard treatment. Patients were followed up for 12 months or till the development of MI.
Patients treated with cod liver oil had comparatively fewer incidences of MI; however, the difference was not significant (p-value: 0.09). Furthermore, the difference was non-significant for both fatal and non-fatal MI. The relative risk for total MI incidence was 0.70 (0.44-1.10).
According to our study, adding cod liver oil to the diet does not play a major role in reducing the risk of MI. Further large-scale studies are needed to understand the role of cod liver oil in reducing the risk of CV events, including MI.
长期以来,ω-3脂肪酸已被证明可降低心血管疾病(CV)的发病率。ω-3脂肪酸主要以二十碳五烯酸(EPA)和二十二碳六烯酸的形式存在于鱼油中。发现鱼肝油中这些ω-3脂肪酸的浓度很高。本研究旨在探讨使用鱼肝油对降低高危患者心肌梗死(MI)发病率的益处。
这项开放标签、安慰剂对照的双臂干预研究于2018年1月至2021年1月在一家三级护理医院的内科和心脏病科进行。在此期间,870名有心血管事件风险的患者在获得知情同意后被纳入研究。研究组除接受当前治疗外,每天服用415毫克无标签瓶装鱼肝油,对照组在标准治疗基础上不接受额外治疗。对患者进行12个月的随访或直至发生心肌梗死。
接受鱼肝油治疗的患者发生心肌梗死的发生率相对较低;然而,差异不显著(p值:0.09)。此外,致命性和非致命性心肌梗死的差异均不显著。总心肌梗死发生率的相对风险为0.70(0.44-1.10)。
根据我们的研究,在饮食中添加鱼肝油对降低心肌梗死风险没有主要作用。需要进一步开展大规模研究,以了解鱼肝油在降低包括心肌梗死在内的心血管事件风险中的作用。